Conference Track

Metabolic Complications and Lipodystrophy

Source: CCO Official Conference Coverage of the 2006 International AIDS Conference

Capsule Summaries

Micronutrient Supplementation May Improve CD4+ Cell Counts in HIV-Infected Patients on HAART
Selenium Supplementation of HAART Associated With Increased CD4+ Cell Counts in HIV-Infected Nigerians
HIV-Positive Women at Higher Risk for Metabolic Syndrome Than HIV-Negative Women
Receipt of Stavudine Plus Didanosine and Receipt of Nelfinavir Combined With Zidovudine/Lamivudine Associated With Lipoatrophy in ACTG 384
In Utero Exposure to NRTIs Not Generally Associated With Risk of Mitochondrial Dysfunction in HIV-Uninfected Children, Possible Association With Late Lamivudine Use
Inhibition of DNA Polymerase Gamma by NRTIs Does Not Appear to Explain Depletion of Mitochondrial DNA Observed in Lipoatrophic HIV-Infected Patients
Recombinant Human Growth Hormone Reduces Visceral Fat in HIV-Infected Patients With Adipose Redistribution Syndrome

Expert Analysis

Metabolic Complications and Lipodystrophy

Faculty:

Judith S. Currier, MD, MSc
Donald P. Kotler, MD
Jens D. Lundgren, MD, DMSc

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss results from epidemiologic studies of the prevalence and risk factors associated with cardiovascular events and metabolic syndrome in HIV-infected patients
Review data on the potential metabolic consequences of antiretroviral classes and specific antiretroviral drugs
Describe results on the use of recombinant human growth hormone as a therapeutic intervention for lipodystrophy in HIV-infected patients

CME CREDIT INFORMATION

Release Date: 10/03/06

Expiration Date: 10/02/07

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.2 Nursing CE credits

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.